FOCUS4 Trial Investigators2022-12-192022-12-192022-04-01FOCUS4 Trial Investigators 2022, 'Experiences of running a stratified medicine adaptive platform trial : Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer', Clinical Trials, vol. 19, no. 2, pp. 146-157. https://doi.org/10.1177/174077452110698791740-7745RIS: urn:C98A67A9776A8D9632D418E08FCEDB42ORCID: /0000-0002-8402-8670/work/107489650https://hdl.handle.net/2164/19747Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: FOCUS4 was co-funded by the Medical Research Council (MRC)/National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) Programme and Cancer Research UK (CRUK) in April 2013. A subsequent AstraZeneca educational grant in 2017 funded the translational aspects of FOCUS4-C. Supply and distribution of AZD8931 for FOCUS-D and AZD1775 for FOCUS4-C were provided by AstraZeneca Ltd. Supply and distribution of aspirin and placebo for FOCUS4-B were provided by Bayer. The MRC Clinical Trials Unit at UCL receives core funding from the MRC within UK Research and Innovation (UKRI) (Budget: MC_UU_12023/20).121080596engSDG 3 - Good Health and Well-beingMetastaticcolorectal cancerbiomarkerstratifiedclinical trialmulti-arm multi-stageadaptivecomplex innovative designR MedicineMedical Research Council (MRC)MC_UU_12023/20National Institute for Health Research (NIHR)Cancer Research UKSupplementary DataRJournal article10.1177/17407745211069879192